In an article in Nature 10 years ago, 2010 Aug 19; 466 (7309): 935-40, GSK provided the complete structure of the drug and the target-the composite structure of the three molecules of GSK299423-DNA-gyrase. The FDA and Without compulsory requirements, GSK's move is completely beyond the medicine itself. As a partner of pharmaceutical R&D companies, we also understand that the biggest enemy of pharmaceutical R&D companies is disease! Persevere in the pursuit of contributing to the progress of the motherland's pharmaceutical industry, continuous learning and continuous progress. Work together for China's pharmaceutical industry!

       Since its establishment in February 2017, Jean Biotechnology has adhered to the working principle of "winning first, seeking war", adhering to the business philosophy of honest service, practicing promises, and constantly improving the company's work process and attitude in order to provide customers with faster ,better service. In 2018, it reached in-depth cooperation with Beijing Blue Angle Medical and other companies. Since the launch of clinical drug supply and clinical recruitment, it has fulfilled its promise to provide sufficient and punctual trial drug and clinical services for the cooperative unit. At present, the cooperation projects Junshi-Esophageal Cancer; Development-Prostate Cancer; Coron-Nasopharyngeal Cancer are all proceeding smoothly. A professional team has created a prosperous age, and we promise to serve as a catalyst for the recruitment of trial subjects, not only in the supply of clinical drugs, but also in clinical recruitment, to provide the most efficient services.
       
    Do not forget the original intention, the young eagle takes off. As a loyal partner of pharmaceutical companies and R&D units, we will continue to contribute to the pharmaceutical industry.